Skip to main content
Caplight Logo









ImmuONE

ImmuONE

Private
StevenageHealthcare & Life Scienceshttps://immuone.com/

Last Round

VC Round

Mar 13, 2025

Total Funding Raised

$2.4M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

ImmuONE is a biotechnology company that provides innovative respiratory in vitro cell culture products and contract research services for inhalation safety testing.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Compliance

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

in vitro lung modelsinhalation safety testinganimal testing alternativesNAMsnew approach methodologies3D cell culturecontract research organizationCROpreclinical safetyhigh-content imagingcell paintingorgan-on-a-chiptoxicology testingdrug discoveryinhalation toxicology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImmuONE Comparables

Compare ImmuONE with similar companies based on industry and business-model similarity.

ImmuONE comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Epithelix
84%
AlveoliX AG
79%
Dynamic42
79%

ImmuONE Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundMar 13, 2025
SeedOct 26, 2023

Key People

Founding team and executive leadership

Abigail Martin

CEO

Executive Team

Jonathan Green

Interim Chief Operating Officer

Executive Team

ImmuONE Investors

Notable investors and investment history

ImmuONE investors
InvestorRounds
Pioneer GroupSeed, VC Round
British Business BankSeed, VC Round
Mercia VenturesVC Round, Seed
Mercia VenturesVC Round, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 19, 2026

    Monthly visitors increased 174% MoM, reaching 2K.

  • Apr 16, 2026

    Monthly visitors increased 43% MoM.

ImmuONE Filings

Explore SEC and related filing metadata, where available.

ImmuONE filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ImmuONE's valuation, stock price, and market status.

Is ImmuONE a public or private company?

ImmuONE is a private company.

What is the current stock price of ImmuONE?

ImmuONE is a private company with no public stock price. No recent secondary market data is available.

How much is ImmuONE worth (valuation)?

Valuation information for ImmuONE is not publicly available.

Can I buy ImmuONE stock?

ImmuONE shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ImmuONE's last funding round?

ImmuONE's most recent funding round was Seed on March 13, 2025.

Who are the main investors in ImmuONE?

Key investors in ImmuONE include Mercia Ventures.

Will ImmuONE IPO soon?

No public IPO plans have been announced for ImmuONE.

How can I track ImmuONE secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ImmuONE's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersStevenage
Employee Range16
Year Founded2019
Last FundingMar 13, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?